DiaMedica Therapeutics
NASDAQ:DMACDiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. The company develops treatments for neurological disorders and cardio-renal disease. Its lead candidate is DM199, a pharmaceutically active recombinant form of the kallikrein-1 protein for the treatment of acute ischemic stroke and other vascular diseases. It is also developing DM300 that is in preclinical stage of development for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Endonovo Therapeutics
OTCMKTS:ENDVEndonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardiovascular diseases, chronic kidney, liver diseases, non-alcoholic steatohepatitis, cardiovascular and peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concussion syndrome, stroke, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.
Marker Therapeutics
NASDAQ:MRKRMarker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma and selected solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia (AML) and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing MT-401, which is in Phase 2 clinical trial for the treatment of post-transplant AML; MT-401-OTS for the treatment of AML; and MT-601 for the treatment of pancreatic cancer and lymphoma. Marker Therapeutics was founded in 1999 and is headquartered in Houston, Texas.
Onconova Therapeutics
NASDAQ:ONTXOnconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Otonomy
NASDAQ:OTICOtonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.